From Monoamine Oxidase Inhibition to Antiproliferative Activity: New Biological Perspectives for Polyamine Analogs.

Giulia Nordio, Francesco Piazzola, Giorgio Cozza, Monica Rossetto, Manuela Cervelli, Anna Minarini, Filippo Basagni, Elisa Tassinari, Lisa Dalla Via, Andrea Milelli, Maria Luisa Di Paolo
Author Information
  1. Giulia Nordio: Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.
  2. Francesco Piazzola: Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.
  3. Giorgio Cozza: Department of Molecular Medicine, University of Padova, 35131 Padova, Italy. ORCID
  4. Monica Rossetto: Department of Molecular Medicine, University of Padova, 35131 Padova, Italy. ORCID
  5. Manuela Cervelli: Department of Science, University of Rome "Roma Tre", 00146 Rome, Italy. ORCID
  6. Anna Minarini: Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, 40126 Bologna, Italy. ORCID
  7. Filippo Basagni: Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, 40126 Bologna, Italy. ORCID
  8. Elisa Tassinari: Department for Life Quality Studies, Alma Mater Studiorum-University of Bologna, 47921 Rimini, Italy.
  9. Lisa Dalla Via: Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy. ORCID
  10. Andrea Milelli: Department for Life Quality Studies, Alma Mater Studiorum-University of Bologna, 47921 Rimini, Italy. ORCID
  11. Maria Luisa Di Paolo: Department of Molecular Medicine, University of Padova, 35131 Padova, Italy. ORCID

Abstract

Monoamine oxidases (MAOs) are well-known pharmacological targets in neurological and neurodegenerative diseases. However, recent studies have revealed a new role for MAOs in certain types of cancer such as glioblastoma and prostate cancer, in which they have been found overexpressed. This finding is opening new frontiers for MAO inhibitors as potential antiproliferative agents. In light of our previous studies demonstrating how a polyamine scaffold can act as MAO inhibitor, our aim was to search for novel analogs with greater inhibitory potency for human MAOs and possibly with antiproliferative activity. A small in-house library of polyamine analogs (-) was selected to investigate the effect of constrained linkers between the inner amine functions of a polyamine backbone on the inhibitory potency. Compounds and , characterized by a dianiline () or dianilide () moiety, emerged as the most potent, reversible, and mainly competitive MAO inhibitors (Ki < 1 μM). Additionally, they exhibited a high antiproliferative activity in the LN-229 human glioblastoma cell line (GI < 1 μM). The scaffold of compound could represent a potential starting point for future development of anticancer agents endowed with MAO inhibitory activity.

Keywords

References

  1. Oncotarget. 2016 Jan 19;7(3):3379-93 [PMID: 26689994]
  2. Antioxid Redox Signal. 2019 Jan 20;30(3):314-332 [PMID: 29065711]
  3. J Neural Transm (Vienna). 2018 Nov;125(11):1519-1551 [PMID: 29637260]
  4. J Med Chem. 2022 Feb 10;65(3):2208-2224 [PMID: 35005974]
  5. Biomedicines. 2022 Mar 08;10(3): [PMID: 35327428]
  6. Sci Immunol. 2021 May 14;6(59): [PMID: 33990379]
  7. Nat Rev Neurosci. 2006 Apr;7(4):295-309 [PMID: 16552415]
  8. J Urol. 2008 Nov;180(5):2206-11 [PMID: 18804811]
  9. Nat Commun. 2021 Jun 10;12(1):3530 [PMID: 34112755]
  10. Amino Acids. 2010 Feb;38(2):383-92 [PMID: 20012115]
  11. J Biol Chem. 2005 Apr 22;280(16):15761-6 [PMID: 15710600]
  12. Bioorg Med Chem. 2007 Mar 15;15(6):2312-21 [PMID: 17276075]
  13. Arch Biochem Biophys. 1997 Jan 1;337(1):137-42 [PMID: 8990278]
  14. ACS Med Chem Lett. 2022 Jan 20;13(2):319-326 [PMID: 35178189]
  15. J Neural Transm (Vienna). 2018 Nov;125(11):1553-1566 [PMID: 30259128]
  16. Int J Biol Sci. 2020 Aug 1;16(14):2692-2703 [PMID: 32792865]
  17. Neurochem Int. 2008 Jan;52(1-2):230-4 [PMID: 17624626]
  18. Toxicol In Vitro. 2014 Apr;28(3):403-10 [PMID: 24373881]
  19. Eur J Med Chem. 2018 Feb 10;145:445-497 [PMID: 29335210]
  20. Int J Mol Sci. 2022 Oct 04;23(19): [PMID: 36233054]
  21. Anal Biochem. 1976 May 7;72:248-54 [PMID: 942051]
  22. Molecules. 2022 Nov 13;27(22): [PMID: 36431918]
  23. J Med Chem. 2009 Aug 13;52(15):4551-73 [PMID: 19534534]
  24. Anal Biochem. 1997 Nov 15;253(2):169-74 [PMID: 9367499]
  25. Mar Drugs. 2014 May 28;12(6):3138-60 [PMID: 24879541]
  26. Molecules. 2019 May 25;24(10): [PMID: 31130597]
  27. Nat Rev Drug Discov. 2007 May;6(5):373-90 [PMID: 17464296]
  28. Biochem Pharmacol. 1982 Nov 15;31(22):3555-61 [PMID: 6817759]
  29. Ageing Res Rev. 2021 Mar;66:101256 [PMID: 33434685]
  30. Nat Rev Cancer. 2018 Nov;18(11):681-695 [PMID: 30181570]
  31. Oncol Rep. 2013 Oct;30(4):1587-92 [PMID: 23900512]
  32. J Neurooncol. 2019 Nov;145(2):287-294 [PMID: 31556016]
  33. Curr Ther Res Clin Exp. 2020 Oct 28;93:100610 [PMID: 33245296]
  34. Prostate Cancer Prostatic Dis. 2021 Mar;24(1):61-68 [PMID: 32123315]
  35. Biomolecules. 2023 Feb 09;13(2): [PMID: 36830711]
  36. J Med Chem. 2007 Nov 15;50(23):5848-52 [PMID: 17915852]
  37. J Chem Theory Comput. 2009 Jun 9;5(6):1632-9 [PMID: 26609855]
  38. Bioorg Med Chem. 2023 Sep 7;92:117425 [PMID: 37544256]
  39. Molecules. 2021 Oct 04;26(19): [PMID: 34641563]
  40. Amino Acids. 2012 Feb;42(2-3):913-28 [PMID: 21858471]
  41. Molecules. 2020 May 11;25(9): [PMID: 32403270]
  42. J Clin Invest. 2014 Jul;124(7):2891-908 [PMID: 24865426]
  43. Hepatol Res. 2018 Nov;48(12):967-977 [PMID: 29923661]
  44. Arch Pharm (Weinheim). 2023 Jul;356(7):e2300091 [PMID: 37021551]
  45. J Biol Chem. 2018 Sep 7;293(36):14040-14064 [PMID: 30021838]
  46. Int J Mol Sci. 2020 Apr 17;21(8): [PMID: 32316576]
  47. Crit Rev Clin Lab Sci. 2015;52(6):284-300 [PMID: 26287391]
  48. Front Oncol. 2023 Feb 13;13:1137050 [PMID: 36860320]
  49. J Enzyme Inhib Med Chem. 2019 Dec;34(1):740-752 [PMID: 30829081]
  50. Medchemcomm. 2012;3(1):14-21 [PMID: 23293738]
  51. Oncol Lett. 2018 Mar;15(3):3245-3251 [PMID: 29435065]
  52. Nat Commun. 2020 Jun 1;11(1):2689 [PMID: 32483206]
  53. J Med Chem. 2009 Dec 10;52(23):7873-7 [PMID: 19954251]
  54. J Cancer Res Clin Oncol. 2010 Nov;136(11):1761-71 [PMID: 20204405]
  55. Oncotarget. 2016 Mar 22;7(12):13842-53 [PMID: 26871599]

Grants

  1. BIRD 213012/Institutional grants from the University of Padova

MeSH Term

Humans
Male
Monoamine Oxidase
Polyamines
Monoamine Oxidase Inhibitors
Glioblastoma
Prostatic Neoplasms

Chemicals

Monoamine Oxidase
Polyamines
Monoamine Oxidase Inhibitors

Word Cloud

Created with Highcharts 10.0.0MAOantiproliferativepolyamineactivityMAOsstudiesinhibitorsanalogsinhibitoryMonoamineoxidasesnewcancerglioblastomapotentialagentsscaffoldpotencyhuman<1μMLN-229well-knownpharmacologicaltargetsneurologicalneurodegenerativediseasesHoweverrecentrevealedrolecertaintypesprostatefoundoverexpressedfindingopeningfrontierslightpreviousdemonstratingcanactinhibitoraimsearchnovelgreaterpossiblysmallin-houselibrary-selectedinvestigateeffectconstrainedlinkersinneraminefunctionsbackboneCompoundscharacterizeddianilinedianilidemoietyemergedpotentreversiblemainlycompetitiveKiAdditionallyexhibitedhighcelllineGIcompoundrepresentstartingpointfuturedevelopmentanticancerendowedOxidaseInhibitionAntiproliferativeActivity:NewBiologicalPerspectivesPolyamineAnalogscellsdockingmonoamine

Similar Articles

Cited By (2)